Blanket purchase agreement for qutenza
Ended Awarded Last action
- Contract number
- 36E79719A0017
- Awardee
-
Averitas Pharma, Inc. UEI QU48MTF1KBT5
- Awarding agency
-
National Acquisition Center
Headquarters, Department of Veterans Affairs
- Task orders
- 0
Award facts
- Opportunity
-
- VA797P12Q0002 Solicitation number
- Last date to order 100% complete
- IDV ceiling
- $225,000.00
- Award type
- Single award
- Who can order
- Only the awarding agency
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
Award details come from SAM.gov/FPDS.
About this IDV
This Blanket Purchase Agreement was awarded by the Department of Veterans Affairs National Acquisition Center to Averitas Pharma Inc., a foreign-owned, for-profit manufacturer of goods, under the Pharmaceuticals and Drugs GSA Schedule. The BPA aims to procure Qutenza, a dermatologic patch used to treat neuropathic pain, for $225,000 over a five-year period from May 2019 through March 2024.
The BPA functions as an indefinite-delivery vehicle for ordering Qutenza to meet the needs of Veterans Affairs medical facilities nationwide. It establishes fixed pricing and delivery terms for the drug, streamlining the acquisition process compared to issuing individual purchase orders. As a single-award agreement, Averitas Pharma serves as the sole provider of Qutenza under the BPA. No set-asides were applied in awarding the contract.
The BPA aims to facilitate effective treatment of neuropathic pain, a condition commonly experienced by veterans, through a non-opioid prescription medication. It consolidates ordering of Qutenza to reduce administrative costs and ensure a reliable supply for VA medical centers while taking advantage of pre-negotiated GSA Schedule pricing. The five-year period of performance provides adequate time for patients to receive ongoing therapy as clinically indicated.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Legal Contract Cancellation | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Exercise an Option | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Exercise an Option | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Exercise an Option | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Exercise an Option | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $0 |
Show all 13
Quick answers
Who was awarded contract 36E79719A0017?
36E79719A0017 was awarded to Averitas Pharma, Inc. by National Acquisition Center (Headquarters) on May 1, 2019.
How much is contract 36E79719A0017 worth?
36E79719A0017's own ceiling is $225,000.
Who can order from contract 36E79719A0017?
36E79719A0017 is a single award blanket purchase agreement. Only the awarding agency can place orders on it.
Is contract 36E79719A0017 under another contract?
Yes. 36E79719A0017 is a blanket purchase agreement under 36F79719D0131, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36E79719A0017 competed?
The extent of competition for 36E79719A0017 was full and open competition. The government received 1 offer.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV